28A5 Dalakas, Marinos - Thomas Jefferson University - Thomas Jefferson University
mcd003

Marinos C. Dalakas, MD, FAAN

Contact Dr. Dalakas

901 Walnut Street
4th Floor
Philadelphia, PA 19107

(215) 955 -7865
(215) 955-9976 fax

Most Recent Peer-reviewed Publications

  1. Treating myasthenia on consensus guide: Helpful and challenging but still unfinished business
  2. Necrotising autoimmune myopathy (NAM): Antibodies seem to be specific markers in aiding diagnosis
  3. Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM
  4. Close to the node but far enough
  5. Viruses in IBM: Hit-and-run, hide and persist, or irrelevant?
  6. Neuro-Immunotherapies: A 30-year Retrospective of an Overwhelming Success and a Brighter Future
  7. Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials
  8. Efficacy of Intravenous Immunoglobulin in Neurological Diseases
  9. Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity
  10. Progressive encephalomyelitis with rigidity and myoclonus (PERM): Brucellosis as a possible triggering factor and long-term follow-up therapy with rituximab
  11. Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease
  12. Immunization of mice with a peptide derived from the HTLV-1 TAX1BP1 protein induces cross-reactive antibodies against aquaporin 4
  13. Follow-up nerve conduction studies in CIDP after treatment with IGIV-C: Comparison of patients with and without subsequent relapse
  14. HMGB1 and RAGE in skeletal muscle inflammation: Implications for protein accumulation in inclusion body myositis
  15. Pathogenesis of immune-mediated neuropathies
  16. Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders
  17. Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders
  18. Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders
  19. Inflammatory muscle diseases inflammatory muscle diseases
  20. Future perspectives in target-specific immunotherapies of myasthenia gravis
0